Meliglix 25 Mg (Sitagliptin)

Sitagliptin blocks the enzyme dipeptidyl peptidase‑4 (DPP‑4), preventing the breakdown of the incretin hormones GLP‑1 and GIP. Higher incretin levels enhance glucose‑dependent insulin secretion and suppress glucagon release, leading to lower blood glucose levels.

The prescribed dose of sitagliptin is determined by the treating clinician based on individual patient factors such as renal function and concomitant therapy. A common starting point is 25 mg taken once daily, but the exact regimen should follow the prescriber’s order.

Safety of sitagliptin during pregnancy and lactation has not been established. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and this decision must be made by a qualified healthcare professional.

To order Meliglix, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Meliglix (sitagliptin) belongs to the DPP‑4 inhibitor class, offering glucose‑dependent insulin release without causing weight gain or hypoglycemia when used alone. Compared with sulfonylureas, it has a lower risk of hypoglycemia, and unlike metformin, it does not cause gastrointestinal intolerance, making it a useful alternative or add‑on therapy.

Store Meliglix tablets at ambient temperature, preferably below 25 °C. Keep the product in its original blister or bottle, protect it from moisture and direct sunlight, and ensure the container is tightly closed when not in use.

Meliglix is taken orally as a tablet. Swallow the tablet whole with a glass of water, with or without food, once daily as directed by the prescriber.

Serious adverse events associated with sitagliptin include acute pancreatitis, severe allergic reactions such as Stevens‑Johnson syndrome, and disabling joint pain (arthralgia). Patients should seek immediate medical attention if they experience persistent abdominal pain, rash with blistering, or unexplained severe joint discomfort.

Meliglix should be avoided in patients with a known hypersensitivity to sitagliptin or any excipients, those with a history of pancreatitis, and individuals with severe renal impairment unless dose adjustments are made under medical supervision.